LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same

US9783599B2 · kind B2 · utility

Assignee

• Patrys Limited · AU

Inventors

• Heinz Peter Vollmers · Coburg, DE
• Stephanie Ute Brandlein · Zellingen, DE
• Andreas Thalheimer · Würzburg, DE
• Leodevico Luna Ilag · Melbourne, AU
• Barbara Power · Melbourne, AU
• Lishanthi Udabage · Cockatoo, AU
• Frank Hensel · Itzehoe, DE
• Frank J. Schoenen · Lawrence, US
• Arndt-Rene Kelter · Bornheim, DE
• Christopher Garth Hosking · Melbourne, AU

Key dates

• Filing date: Mar 14, 2014
• Grant date: Oct 10, 2017
• Expiry date: Mar 14, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides LM-1 antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. The invention also provides antibodies, functional fragments, modified and variant forms that bind to LM-1 antigen (e.g., NONO/nmt55). Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One method includes treating metastasis of a neoplasia, tumor or cancer in a subject in need of treatment by administering to the subject an amount of a LM-1 antibody, an antibody that binds to LM-1 antigen, or a functional fragment thereof, effective to treat metastasis of the neoplasia, tumor or cancer in the subject.